| Literature DB >> 30453627 |
Matti Marklund1,2, Andrew P Morris3, Anubha Mahajan4, Erik Ingelsson5,6,7,8, Cecilia M Lindgren9,10, Lars Lind11, Ulf Risérus12.
Abstract
Fatty acid desaturases (FADS) catalyze the formation of unsaturated fatty acids and have been related to insulin sensitivity (IS). FADS activities differ between tissues and are influenced by genetic factors that may impact the link to IS. Genome-wide association studies of δ-5-desaturase (D5D), δ-6-desaturase (D6D) and stearoyl-CoA desaturase-1 (SCD) activities (estimated by product-to-precursor ratios of fatty acids analyzed by gas chromatography) in serum cholesterol esters (n = 1453) and adipose tissue (n = 783, all men) were performed in two Swedish population-based cohorts. Genome-wide significant associated loci were evaluated for associations with IS measured with a hyperinsulinemic euglycemic clamp (n = 554). Variants at the FADS1 were strongly associated with D5D in both cholesterol esters (p = 1.9 × 10-70) and adipose tissue (p = 1.1 × 10-27). Variants in three further loci were associated with D6D in cholesterol esters (FADS2, p = 3.0 × 10-67; PDXDCI, p = 4.8 × 10-8; and near MC4R, p = 3.7 × 10-8) but no associations with D6D in adipose tissue attained genome-wide significance. One locus was associated with SCD in adipose tissue (PKDL1, p = 2.2 × 10-19). Genetic variants near MC4R were associated with IS (p = 3.8 × 10-3). The FADS cluster was the main genetic determinant of estimated FADS activity. However, fatty acid (FA) ratios in adipose tissue and cholesterol esters represent FADS activities in separate tissues and are thus influenced by different genetic factors with potential varying effects on IS.Entities:
Keywords: Genome-wide association study (GWAS); Insulin sensitivity; adipose tissue; cholesterol ester; desaturase; fatty acid
Mesh:
Substances:
Year: 2018 PMID: 30453627 PMCID: PMC6266021 DOI: 10.3390/nu10111791
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Clinical characteristics of individuals in ULSAM and PIVUS with genotype data and estimated desaturase activity in cholesterol esters. 1
| ULSAM ( | PIVUS ( | |
|---|---|---|
| Age | 71.3 (0.4) | 70.2 (0.2) |
| Women (%) | 0 | 49 |
| BMI (kg/m2) | 26.3 (3.4) | 27.0 (4.4) |
| Antihypertensive treatment (%) | 37 | 31 |
| Total cholesterol (mmol/L) | 5.8 (1.0) | 5.4 (1.0) |
| HDL cholesterol (mmol/L) | 1.3 (0.3) | 1.5 (0.4) |
| Triglycerides (mmol/L) | 1.5 (0.8) | 1.3 (0.6) |
| Lipid lowering treatment (%) | 9.4 | 15.9 |
| Fasting plasma glucose (mmol/L) | 5.8 (1.5) | 6.0 (1.8) |
| Glucose disposal, M (mg/kg/min) | 5.2 (2.1) | N/A |
| Diabetes treatment (%) | 6.5 | 6.5 |
| Never smokers (%) | 40 | 48 |
| Previous smokers (%) | 40 | 41 |
| Current smokers (%) | 20 | 11 |
Values are mean (SD) or percentage. 1 PIVUS, Prospective Investigation of Uppsala Seniors; ULSAM, Uppsala Longitudinal Study of Adult Men; HDL, high-density lipoprotein; BMI, body mass index; M, in vivo insulin-mediated glucose disposal.
Figure 1Estimated δ-5-desaturase (D5D) activity in cholesterol esters (a) and adipose tissue (b) by genotype at rs174549. Values are means and error bars represent 95% confidence intervals of means. D5D activity was estimated as the ratio of arachidonic acid (20:4n−6) and dihomo-gamma-linolenic acid (20:3n−6).
Common variants (MAF ≥ 5%) with p < 1 × 10−8. a
| Desaturase | Gene | Lead SNP | Chr:Position (b37) | EAF | Effect Allele/ | Serum | Adipose Tissue | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Direction |
|
| Direction |
|
| ||||||
| D5D |
| rs174549 | 11:61571382 | 0.33 | A/G | − | 1.9 × 10−70 | 1448 | − | 1.1 × 10−27 | 766 |
| D6D |
| rs138194593 | 11:61620703 | 0.63 | CTCTT/C | + | 3.0 × 10−67 | 1448 | − | 7.9 × 10−1 | 611 |
| D6D |
| rs6498540 | 16:15130594 | 0.71 | A/G | + | 4.8 × 10−8 | 1448 | − | 2.9 × 10−1 | 611 |
| D6D | near | rs9957425 | 18:57462103 | 0.61 | T/C | + | 3.7 × 10−8 | 1448 | − | 9.0 × 10−1 | 611 |
| SCD |
| rs603424 | 10:102075479 | 0.14 | A/G | − | 1.6 × 10−4 | 1453 | − | 2.2 × 10−19 | 783 |
a A, adenine; C, cytosine; Chr, chromosome; b37, NCBI build 37; D5D, δ-5-desaturase; D6D, δ-6-desaturase; EAF, effect allele frequency; FADS1, fatty acid desaturase 1; FADS2, fatty acid desaturase 2; G, guanine; MC4R, melanocortin 4 receptor; PDXDC1, pyridoxal-dependent decarboxylase domain containing 1; PKD2L1, polycystic kidney disease 2-like 1; SCD, Stearoyl-CoA desaturase; T, thymine.
Associations of significant desaturase loci with BMI and metabolic traits. a
| Gene | rs ID b | Chr:Position (b37) | Effect Allele | EAF | ULSAM + PIVUS Meta-Analysis ( | ULSAM ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDL Cholesterol | Triglycerides | BMI | HOMA-IR | M-Value | ||||||||||
| Direction |
| Direction |
| Direction |
| Direction |
| Direction |
| |||||
|
| rs174549 | 11:61571382 | A | 0.33 | − | 2.0 × 10−2 | + | 1.8 × 10−1 | + | 5.4 × 10−1 | + | 6.9 × 10−1 | − | 7.6 × 10−1 |
|
| rs968567 | 11:61595564 | T | 0.15 | − | 2.4 × 10−1 | + | 5.5 × 10−1 | + | 1.1 × 10−1 | + | 5.6 × 10−2 | − | 2.1 × 10−1 |
|
| rs138194593 | 11:61620703 | CTCTT | 0.63 | + | 9.3 × 10−3 | − | 4.2 × 10−1 | − | 1.8 × 10−1 | − | 7.9 × 10−1 | + | 5.3 × 10−1 |
|
| rs2072113 | 11:61604967 | T | 0.17 | − | 7.6 × 10−2 | + | 3.9 × 10−1 | − | 7.3 × 10−1 | − | 2.5 × 10−1 | + | 5.8 × 10−1 |
|
| rs6498540 | 16:15130594 | A | 0.71 | + | 7.8 × 10−1 | − | 8.5 × 10−1 | − | 4.2 × 10−1 | + | 3.7 × 10−1 | + | 7.6 × 10−1 |
| near | rs9957425 | 18:57462103 | T | 0.61 | − | 2.2 × 10−1 | + c | 2.1 × 10−3 | + c | 7.4 × 10−4 | + | 7.1 × 10−2 | − c | 3.8 × 10−3 |
|
| rs603424 | 10:102075479 | A | 0.14 | + | 8.4 × 10−1 | + | 5.2 × 10−1 | + | 8.8 × 10−1 | + | 8.8 × 10−1 | − | 7.6 × 10−2 |
a Chr, chromosome; b37, NCBI build 37; EAF, effect allele frequency; FADS1, fatty acid desaturase 1; FADS2, fatty acid desaturase 2; PDXDC1, pyridoxal-dependent decarboxylase domain containing 1; MC4R, melanocortin 4 receptor; PKD2L1, polycystic kidney disease 2-like 1; PIVUS, Prospective Investigation of Uppsala Seniors; ULSAM, Uppsala Longitudinal Study of Adult Men; HDL, high-density lipoprotein; BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance. b Reference SNP ID number. c Significant association after adjustment for multiple testing.